Yale Cancer Center (YCC) researchers at Yale School of Medicine will present new research at the 47th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center from December 10 to 13.
The international symposium will reveal new, leading-edge breast cancer research on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium will include more than 10,000 clinicians, scientists, patient advocates, and health care professionals from more than 100 countries around the world. The scientific program consists of formal lectures and oral presentations in conference halls, poster presentations, forums, and case discussions in clinical, translational, basic research.
YCC experts will discuss a variety of topics ranging from novel therapeutics for HER2+ breast cancers, dosing optimization in breast cancer trials, and new findings on different genomic ancestries for advanced breast cancers. SABCS YCC presentations include:
Tuesday, December 10
FDA Special Session: New Drug Approvals
Speaker: Eric Winer, MD
Clinical Workshop Session: Dose Optimization in Breast Medical Oncology
Speaker: Pat LoRusso, DO, FAACR
Wednesday, December 11
New Insights into Immune Biomarkers
Speaker: David Rimm, MD, PhD
Genomic Landscape in Advanced Breast Cancer Across Different Genomic Ancestries
Presenter: Alejandro Rios Hoyo, MD
Thursday, December 12
Novel HER2 Therapeutics
Speaker: Ian Krop, MD, PhD
Predictors of Survival
Speaker: Tara Sanft, MD
Prevalence of actionable genomic alterations (GA) and predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitor (ICI) effectiveness in HR(+)HER2(-) metastatic breast cancer (MBC)
Presenter: Mariya Rozenblit, MD
Friday, December 13
Immunobiology Impact on Therapeutic Efficacy
Speaker: Lajos Pusztai, MD
For a full list of YCC presentations at SABCS, click here.